Oncology & Cancer

Single-dose PCV13 immunogenic, safe in pediatric oncology

(HealthDay)—For pediatric and adolescent oncology patients, a single-dose 13-valent pneumococcal conjugate vaccine (PCV13) is safe and immunogenic, according to a study published online July 11 in Cancer.

Diseases, Conditions, Syndromes

Study reveals new insight into susceptibility to pneumonia

A new research study of immune responses to pneumococcal vaccines, commonly given to people with compromised immune systems, young children and people over 65, has identified a type of immune cell which is important in generating ...

Pediatrics

Post-PCV13 drop in Streptococcus pneumoniae bacteremia

(HealthDay)—Introduction of seven-valent and 13-valent pneumococcal conjugate vaccine (PCV13) correlated with a reduction in Streptococcus pneumoniae bacteremia, according to a review published online March 10 in Pediatrics.

Medications

MSF challenges Pfizer's India vaccine patent application

Doctors Without Borders has challenged Pfizer's application for an Indian patent for its pneumonia vaccine so cheaper versions can be available to children in poor countries and to humanitarian organizations.

Health

Using price to avoid vaccine shortages

No one worries about vaccine supply—until there's a shortage. New research from Duke University's Fuqua School of Business studied the market tensions that can keep manufacturers out of the business and the price points ...

page 4 from 9